Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label atomoxetine for ADHD in children with special educational needs
2008-004827-44Phase 4Completed
- Sponsor
- King's College London
- Start
- Dec 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of atomoxetine in attention deficit hyperactivity disorder (ADHD), sponsored by King's College London. Primary endpoint: Change in ADHD symptoms (Conners ADHD Index, parent and teacher ratings). Started Dec 2010; status: completed.
02
Drugs
atomoxetine
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on 2008-004827-44.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-004827-44.